Protein Biomarker Druggability Profiling

Overview

Journal J Biomed Inform

Publisher Elsevier

Specialty Medical Informatics

Date 2017 Jan 30

PMID 28131723

Citations 1

Authors

Subramani Mani

Daniel Cannon

Robin Ohls

Tudor Oprea

Stephen Mathias

Karri Ballard

Oleg Ursu

Cristian Bologa

Affiliations

Soon will be listed here.

Abstract

Developing automated and interactive methods for building a model by incorporating mechanistic and potentially causal annotations of ranked biomarkers of a disease or clinical condition followed by a mapping into a contextual framework in disease-linked biochemical pathways can be used for potential drug-target evaluation and for proposing new drug targets. We demonstrate the potential of this approach using ranked protein biomarkers obtained in neonatal sepsis by enrolling 127 infants (39 infants with late onset neonatal sepsis and 88 control infants) and by performing a focused proteomic profile of the sera and by applying the interactive druggability profiling algorithm (DPA) developed by us.

Citing Articles

Leveraging systems biology for predicting modulators of inflammation in patients with COVID-19.

Jung S, Potapov I, Chillara S, Sol A Sci Adv. 2021; 7(6).

PMID: 33536217 PMC: 11323279. DOI: 10.1126/sciadv.abe5735.

References

Aebersold R, Anderson L, Caprioli R, Druker B, Hartwell L, Smith R . Perspective: a program to improve protein biomarker discovery for cancer. J Proteome Res. 2005; 4(4):1104-9. DOI: 10.1021/pr050027n. View

Hood L, Heath J, Phelps M, Lin B . Systems biology and new technologies enable predictive and preventative medicine. Science. 2004; 306(5696):640-3. DOI: 10.1126/science.1104635. View

Liao H, Wu J, Kuhn E, Chin W, Chang B, Jones M . Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum. 2004; 50(12):3792-803. DOI: 10.1002/art.20720. View

Kamburov A, Cavill R, Ebbels T, Herwig R, Keun H . Integrated pathway-level analysis of transcriptomics and metabolomics data with IMPaLA. Bioinformatics. 2011; 27(20):2917-8. DOI: 10.1093/bioinformatics/btr499. View

Sharman J, Benson H, Pawson A, Lukito V, Mpamhanga C, Bombail V . IUPHAR-DB: updated database content and new features. Nucleic Acids Res. 2012; 41(Database issue):D1083-8. PMC: 3531077. DOI: 10.1093/nar/gks960. View

Rosas I, Richards T, Konishi K, Zhang Y, Gibson K, Lokshin A . MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008; 5(4):e93. PMC: 2346504. DOI: 10.1371/journal.pmed.0050093. View

Mayr M, Zhang J, Greene A, Gutterman D, Perloff J, Ping P . Proteomics-based development of biomarkers in cardiovascular disease: mechanistic, clinical, and therapeutic insights. Mol Cell Proteomics. 2006; 5(10):1853-64. DOI: 10.1074/mcp.R600007-MCP200. View

Tsimikas S, Willerson J, Ridker P . C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol. 2006; 47(8 Suppl):C19-31. DOI: 10.1016/j.jacc.2005.10.066. View

Hewitt S, Dear J, Star R . Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol. 2004; 15(7):1677-89. DOI: 10.1097/01.asn.0000129114.92265.32. View

10.

Piliarik M, Bockova M, Homola J . Surface plasmon resonance biosensor for parallelized detection of protein biomarkers in diluted blood plasma. Biosens Bioelectron. 2010; 26(4):1656-61. DOI: 10.1016/j.bios.2010.08.063. View

11.

Petricoin E, Belluco C, Araujo R, Liotta L . The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer. 2006; 6(12):961-7. DOI: 10.1038/nrc2011. View

12.

Whiteaker J, Zhao L, Anderson L, Paulovich A . An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol Cell Proteomics. 2009; 9(1):184-96. PMC: 2808264. DOI: 10.1074/mcp.M900254-MCP200. View

13.

Adkins J, Varnum S, Auberry K, Moore R, Angell N, Smith R . Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics. 2003; 1(12):947-55. DOI: 10.1074/mcp.m200066-mcp200. View

14.

Oprea T, Nielsen S, Ursu O, Yang J, Taboureau O, Mathias S . Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer-Aided Drug Repurposing. Mol Inform. 2012; 30(2-3):100-111. PMC: 3266123. DOI: 10.1002/minf.201100023. View

15.

Danhof M, Alvan G, Dahl S, Kuhlmann J, Paintaud G . Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm Res. 2005; 22(9):1432-7. DOI: 10.1007/s11095-005-5882-3. View

16.

Seibert V, Ebert M, Buschmann T . Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery. Brief Funct Genomic Proteomic. 2005; 4(1):16-26. DOI: 10.1093/bfgp/4.1.16. View

17.

Kovesdi E, Luckl J, Bukovics P, Farkas O, Pal J, Czeiter E . Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics. Acta Neurochir (Wien). 2009; 152(1):1-17. DOI: 10.1007/s00701-009-0463-6. View

18.

Jacobs J, Adkins J, Qian W, Liu T, Shen Y, Camp 2nd D . Utilizing human blood plasma for proteomic biomarker discovery. J Proteome Res. 2005; 4(4):1073-85. DOI: 10.1021/pr0500657. View

19.

Bogdanov M, Matson W, Wang L, Matson T, Saunders-Pullman R, Bressman S . Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain. 2008; 131(Pt 2):389-96. DOI: 10.1093/brain/awm304. View

20.

Doecke J, Laws S, Faux N, Wilson W, Burnham S, Lam C . Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol. 2012; 69(10):1318-25. PMC: 6287606. DOI: 10.1001/archneurol.2012.1282. View